WO2017028625A1 - Timbre pleural/méningé et son procédé de préparation - Google Patents

Timbre pleural/méningé et son procédé de préparation Download PDF

Info

Publication number
WO2017028625A1
WO2017028625A1 PCT/CN2016/087456 CN2016087456W WO2017028625A1 WO 2017028625 A1 WO2017028625 A1 WO 2017028625A1 CN 2016087456 W CN2016087456 W CN 2016087456W WO 2017028625 A1 WO2017028625 A1 WO 2017028625A1
Authority
WO
WIPO (PCT)
Prior art keywords
pleural
meningeal
patch
chitosan
cartilage chitosan
Prior art date
Application number
PCT/CN2016/087456
Other languages
English (en)
Chinese (zh)
Inventor
吴奕光
冯奕清
黎剑辉
江长兵
吴灿光
Original Assignee
深圳市阳光之路生物材料科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市阳光之路生物材料科技有限公司 filed Critical 深圳市阳光之路生物材料科技有限公司
Publication of WO2017028625A1 publication Critical patent/WO2017028625A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
    • C08J5/18—Manufacture of films or sheets

Definitions

  • the invention relates to the technical field of biological materials, in particular to a pleural/meningeal patch and a preparation method thereof.
  • the dura mater and pleura are important functional membrane tissues between the brain and the skull, the inner surface of the chest wall and the upper surface of the chest and the surface of the lung, respectively, with similar biological characteristics and functions.
  • Dural and pleural defects are mainly caused by tumor resection, trauma, inflammation, viral infection and radiation damage. Improper repair of the dura mater often causes cerebrospinal fluid leakage, meningeal tissue adhesion and scar formation of brain tissue. In severe cases, epilepsy can be caused.
  • the chest wall defect not only affects the appearance, but also has different degrees of thoracic internal organ damage, and the area is large. Chest wall defects often cause abnormal breathing, interfere with normal breathing cycle function, and even lead to death. Therefore, studying the ideal dural/pleural repair materials to meet clinical needs has always been a concern of brain surgery and thoracic surgery.
  • the pleural and dura mater alternatives have undergone four processes of autologous materials, foreign materials, biomaterials, and synthetic materials, but all have advantages and disadvantages.
  • a hard brain / meningeal bio-patch material and its preparation method application number 201410373258.6
  • the membrane structure of cattle is used as a material, and the material is sequentially placed in a surfactant solution, a lye
  • the peroxide solution, the glycidyl ether epoxy cross-linking agent solution having a mass percentage concentration of 1-5%, and the phosphate buffer solution are immersed, and the dura mater material is obtained after drying radiation, and the material is likely to cause adhesion. It is not easy to store and disinfect, and may even have an immune response.
  • chitosan is disclosed as a partial deacetylated product of chitin, which has a polysaccharide with mucopolysaccharide. (GAG) has a similar chemical structure and has many excellent properties for tissue engineering scaffolding materials. However, like other natural macromolecules, chitosan has poor mechanical properties in supporting tissue cells. As natural macromolecules and synthetic polyester composites are gradually used in tissue engineering, the mixing of chitosan with synthetic polyester with good mechanical properties can effectively improve the mechanical properties of the materials.
  • Membrane composition the outermost layer is composed of anti-adhesive cross-linked sodium hyaluronate with strong moisturizing, water permeability and gas permeable properties; the gap existing in the patch woven structure can phagot the bacteria causing infection, and the material preparation is complicated and the cost is extremely high. .
  • a composite artificial dura mater and its preparation method application No. 201410627515.4
  • polylactic acid, tricalcium phosphate and polytetrafluoroethylene are mixed at high temperature, and the prepared rubber mixture is mixed with gasoline to form a slurry, which is spun and knitted to obtain an artificial dura mater.
  • the mechanical properties of the material are obtained. Preferably, but its biocompatibility is poor and non-absorbable.
  • the object of the present invention is to provide a pleural/meningeal patch and a preparation method thereof, which solve the technical problems that the prior art has a complicated preparation process, biocompatibility and mechanical properties.
  • the method for preparing a pleural/meningeal patch proposed by the present invention comprises the following steps:
  • the coating film in the step S2 is a spin coating film.
  • the rotational speed of the spin coating film is 2000 to 3000 rad/min, and the time is 9 to 12 s.
  • step S1 the squid cartilage chitosan is dissolved in a solvent at a ratio of solid to liquid of 1.0:100 to 5.0:100 g/ml to obtain the gum solution.
  • the solvent is acetic acid having a mass percent concentration of 2%.
  • the glue liquid is filtered and defoamed.
  • the preparation of the salmon cartilage chitosan in step S1 comprises the following steps:
  • the squid cartilage ⁇ -chitin is dissolved in a NaOH solution having a mass percentage concentration of 30% to 40% at a ratio of solid to liquid of 5.0:100 to 25:100 g/ml, and stirred at 50 to 80 ° C for 1 to 6 hours. After filtration, the first filter residue is obtained;
  • the first filter residue is washed to neutral and then dried to obtain a first salmon cartilage chitosan as the salmon cartilage chitosan of step S1.
  • step S12 the following steps are further included:
  • the first squid cartilage chitosan obtained in step S12 is used as a first intermediate product, and the first intermediate product is dissolved in a mass percentage concentration at a ratio of solid to liquid ratio of 5.0:100 to 25:100 g/ml. 30% ⁇ 40% of the NaOH solution, stirred at 50 ⁇ 80 ° C for 1 ⁇ 6h and then filtered to obtain a second filter residue;
  • the second filter residue is washed to neutrality and then dried to obtain a second salmon cartilage chitosan having a different degree of deacetylation from the first intermediate product as the salmon cartilage chitosan of step S1.
  • step S12 or step S14 the following steps are further included:
  • the first squid cartilage chitosan obtained in step S12 or the second squid cartilage chitosan obtained in step S14 is used as a second intermediate product at a solid-liquid ratio of 5.0:100 to 25:100 g/ml.
  • the second intermediate product is dissolved in a hydrochloric acid solution having a mass percentage concentration of 1% to 5% at room temperature, and sonicated at 60 to 80 ° C for 2 to 8 hours to obtain a mixed solution;
  • the third filter residue is washed to neutrality and then dried to obtain a third salmon cartilage chitosan having a molecular weight different from that of the second intermediate product, as the salmon cartilage chitosan of step S1.
  • the present invention also provides a pleural/meningeal patch which is prepared using any of the above-described methods for preparing a pleural/meningeal patch.
  • the biomaterial chitosan has good antibacterial property, film forming property, biodegradability and biocompatibility, and has the characteristics of rapidly promoting wound healing and preventing tissue adhesion. Therefore, the chitosan film has a pleural and dura mater patch.
  • Potential application value is generally prepared from shrimp and crab shell ⁇ -chitin, which is prepared by strong alkali and high temperature deacetylation method. Its molecular weight is generally low, about 0.1 ⁇ 10 6 , the prepared chitosan Membrane mechanical properties are poor, can not be used as a pleural and dura mater patch in clinical.
  • the invention provides a preparation method for preparing a novel degradable pleural or dura mater and a preparation method thereof, which is prepared by preparing a squid cartilage chitosan with a specific molecular weight and a degree of deacetylation as a raw material, and only comprises a cartilage-containing cartilage.
  • the solid content of chitosan has good dry and wet mechanical properties, and the film thickness of the film is more uniform by the method of spin coating, which eliminates the pores of the film patch and improves its anti-seepage performance.
  • the patch has good antibacterial properties, biocompatibility, biodegradability, and no inflammatory reaction to surrounding tissues, and is used for temporarily replacing the pleura and dura mater of human body defects, thereby effectively promoting the human body.
  • the regenerative repair of the pleura and dura mater is finally degraded and absorbed in the body, so it has high clinical application value.
  • 1 is a comparison diagram of thickness uniformity of a cast film and a spin coating film according to a first embodiment of the present invention
  • FIG. 2 is a graph showing the in vitro enzymatic residual rate of a patch according to a first embodiment of the present invention
  • FIG. 3 is a view showing the inflammation of the patch implanted in the body according to the first embodiment of the present invention.
  • Figure 4 is a diagram showing the enzymatic hydrolysis of a patch according to a first embodiment of the present invention in mice;
  • Figure 5 is a graph showing changes in MDA in serum of mice after patch implantation according to a first embodiment of the present invention; wherein, the first blank column indicates MDA content in serum of normal mice, EG-13, EG-24, EG -49, EG-60 showed the MDA content in the serum of mice on the 13th, 24th, 49th and 60th day of the experimental group, respectively, CG-13, CG-24, CG-49, CG-60 respectively MDA content in the serum of mice on the 13th, 24th, 49th, and 60th day of the group.
  • the preparation method of a pleural/meningeal patch proposed by the invention comprises the following steps:
  • the preparation of the squid cartilage chitosan in step S1 comprises:
  • the squid cartilage ⁇ -chitin or squid cartilage chitosan is dissolved in a 3% by mass concentration of 30% to 40% NaOH solution, at 50-80 After stirring at ° C for 1 to 6 hours, it is filtered to obtain a filter residue;
  • the filter residue obtained in the step S11 is washed to neutrality and then dried to obtain the squid cartilage chitosan used in the step S1.
  • the degree of deacetylation of squid cartilage chitosan was determined by elemental analysis, and the viscosity average molecular weight of squid cartilage chitosan was determined by a dilute solution viscosity method to obtain a series of squid cartilage chitosan as shown in Table 1 below. It can be seen from Table 1 that using different deacetylation conditions (such as alkali concentration, time, temperature), the obtained chimon cartilage chitosan has similar molecular weights and different degrees of deacetylation.
  • the preparation of the squid cartilage chitosan further comprises, after step S12:
  • step S13 The squid cartilage chitosan obtained in step S12 is used as an intermediate product, and the intermediate product is dissolved at a concentration of 1% to 5% by weight of hydrochloric acid at a ratio of a solid-liquid ratio of 5.0:100 to 25:100 g/ml.
  • ultrasonic treatment at 60 ⁇ 80 ° C for 2 ⁇ 8h, to obtain a mixed solution;
  • the filter residue obtained in the step S14 is washed to neutrality and then dried to obtain a squid cartilage chitosan having a molecular weight different from that of the intermediate product, which is used as the squid cartilage chitosan used in the step S1.
  • the degree of deacetylation of squid cartilage chitosan was determined by elemental analysis.
  • the viscosity average molecular weight of squid cartilage chitosan was determined by dilute solution viscosity method, and a series of squid cartilage chitosan as shown in Table 2 below were obtained. As can be seen from Table 2, by changing the sonication time and/or temperature, the obtained cartilage chitosan has a similar degree of deacetylation and a different molecular weight.
  • CS-150 DD (80.00 ⁇ 0.65)%, MW (1.52 ⁇ 0.25) ⁇ 10 6 carp cartilage chitosan.
  • Embodiment 1 is a diagrammatic representation of Embodiment 1:
  • This embodiment provides a method for preparing a pleural/meningeal patch, comprising the following steps:
  • the chitosan film is dried in a blast drying oven at 60 ° C, washed with a dilute alkali solution and deionized water, and again dried in a blast drying oven at 60 ° C to obtain a pleural/meningeal patch.
  • the preparation of the squid cartilage chitosan powder in step S1 comprises:
  • step S1 Since the viscosity of the glue disposed in step S1 is large, the glue of the cast coating film is difficult to spread evenly on the substrate, and the spin coating process is a combination of the viscous force between the glue and the substrate and the centrifugal force caused by the rotation. The action causes the glue to flow on the flat substrate to form a film, and the formed liquid film is flat and has less undulation. Therefore, the squid cartilage chitosan film prepared by the spin coating method has a more uniform thickness and no pores in the film, and the anti-seepage performance is greatly improved. See FIG. 1 for casting film formation and rotation according to the first embodiment of the present invention.
  • the pleural/meningeal patch prepared in this example has a thickness of 0.10 mm, a wet tensile strength of 11.45 ⁇ 0.12 MPa, an elongation at break of 209.64 ⁇ 21.21%, and a swelling ratio of 239%.
  • the specific mechanical properties are shown in Table 3 below. Show:
  • FIG. 2 is a graph showing the in vitro enzymatic residual rate of the patch according to the first embodiment of the present invention.
  • the in vitro enzymatic performance test shows that the patch residual rate decreases with time.
  • the biocompatibility, biodegradability and surrounding tissue inflammation of the patch were evaluated by subcutaneous implantation of a patch test in mice as an experimental group.
  • the mice were not placed in the mice, and the sutures were simply sutured as the control group, and the mice were not treated as the normal group.
  • Macroscopic observations revealed that the wounds in the mice slowly healed, and only two months later the wound had a linear scar.
  • HE staining showed that there was an inflammatory reaction in the early stage of wound healing in the experimental group and the control group, and then the inflammatory reaction gradually disappeared.
  • Masson staining light microscopy revealed that wound tissue in the experimental group and the control group contained a large number of fibroblasts and a large amount of collagen deposition.
  • FIG. 3 is a diagram showing the inflammation of the implanted patch in vivo according to the first embodiment of the present invention.
  • the inflammatory reaction of the wound tissue occurs in the first 24 days after patch implantation. The most intense time is because the wound is not completely healed and the incompatibility caused by the patch in the body causes inflammation; after 24 days, the patch implant material is completely fused with the tissue, and the wound is basically healed, and the inflammatory reaction is gradually reduced; At 60 days, the COX-2/GAPDH ratio was smaller than that of the normal group, indicating that the inflammatory response slowly disappeared.
  • 4 is a diagram showing the enzymatic hydrolysis of a patch according to a specific embodiment 1 of the present invention.
  • the patch is slowly enzymatically absorbed in the body, and the first 13 after implantation. Days, the patch degraded slowly, and then the mouse self-healing ability strengthened, the wound slowly healed, make up Tablet absorption also accelerated; 60 days after patch implantation, the patch residual rate was 58%.
  • 5 is a graph showing the change of MDA in the serum of mice after patch implantation according to the first embodiment of the present invention. By comparing the serum MDA content in the experimental group, the control group and the normal group, the patch is implanted.
  • the MDA content of the experimental group and the control group at 13, 39, and 60 days was higher than that of the normal group, and the MDA content of the control group and the experimental group were basically equal, indicating that the implantation of the patch did not cause additional damage to the mouse tissue cells. Damage, the patch has good biocompatibility.
  • the pleural and dura mater patches prepared by the spin coating method have good dry and wet mechanical properties, more uniform thickness, and eliminate the pores of the membrane. Improve its barrier properties.
  • the patch has good biocompatibility, biodegradability, and no inflammatory response to surrounding tissues.
  • Embodiment 2 is a diagrammatic representation of Embodiment 1:
  • This embodiment provides a method for preparing a pleural/meningeal patch, comprising the following steps:
  • the chitosan film is dried in a blast drying oven at 60 ° C, washed with a dilute alkali solution and deionized water, and again dried in a blast drying oven at 60 ° C to obtain a pleural/meningeal patch.
  • the preparation of the squid cartilage chitosan powder in step S1 comprises:
  • the pleural/meningeal patch prepared in this example has a thickness of 0.12 mm, a wet tensile strength of 9.3 ⁇ 0.27 MPa, an elongation at break of 200.58 ⁇ 10.25%, and a swelling ratio of 156%.
  • Embodiment 3 is a diagrammatic representation of Embodiment 3
  • This embodiment provides a method for preparing a pleural/meningeal patch, comprising the following steps:
  • the chitosan film is dried in a blast drying oven at 60 ° C, washed with a dilute alkali solution and deionized water, and again dried in a blast drying oven at 60 ° C to obtain a pleural/meningeal patch.
  • the preparation of the squid cartilage chitosan powder in step S1 comprises:
  • the pleural/meningeal patch prepared in this example has a thickness of 0.18 mm, a wet tensile strength of 8.29 ⁇ 0.35 MPa, an elongation at break of 189.66 ⁇ 36.72%, and a swelling ratio of 235%.
  • Embodiment 4 is a diagrammatic representation of Embodiment 4:
  • This embodiment provides a method for preparing a pleural/meningeal patch, comprising the following steps:
  • the chitosan film is dried in a blast drying oven at 60 ° C, washed with a dilute alkali solution and deionized water, and again dried in a blast drying oven at 60 ° C to obtain a pleural/meningeal patch. .
  • the preparation of the squid cartilage chitosan powder in step S1 comprises:
  • the pleural/meningeal patch prepared in this example has a thickness of 0.13 mm, a wet tensile strength of 7.43 ⁇ 1.24 MPa, an elongation at break of 154.24 ⁇ 7.48%, and a swelling ratio of 234%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Manufacturing & Machinery (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne un timbre pleural/méningé et son procédé de préparation. Le procédé de préparation comprend les étapes de : S1, dissolution de chitosane de cartilage de calmar en un fluide colloïdal, le degré de désacétylation du chitosane de cartilage de calmar étant supérieur à 60 %, et le poids moléculaire du chitosane de cartilage de calmar étant supérieur à 0,5 * 106 ; et S2, revêtement avec le fluide colloïdal pour obtenir le timbre pleural/méningé. Le timbre pleural/méningé préparé par le procédé est capable de favoriser de manière efficace la régénération et la réparation de la plèvre et la dure-mère d'un corps humain, et est finalement dégradé et absorbé dans le corps, ayant ainsi une valeur d'application clinique supérieure.
PCT/CN2016/087456 2015-08-19 2016-06-28 Timbre pleural/méningé et son procédé de préparation WO2017028625A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510511365.5 2015-08-19
CN201510511365.5A CN105079875A (zh) 2015-08-19 2015-08-19 一种胸膜/脑膜及其制备方法

Publications (1)

Publication Number Publication Date
WO2017028625A1 true WO2017028625A1 (fr) 2017-02-23

Family

ID=54561786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/087456 WO2017028625A1 (fr) 2015-08-19 2016-06-28 Timbre pleural/méningé et son procédé de préparation

Country Status (2)

Country Link
CN (1) CN105079875A (fr)
WO (1) WO2017028625A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105079875A (zh) * 2015-08-19 2015-11-25 深圳市阳光之路生物材料科技有限公司 一种胸膜/脑膜及其制备方法
CN105133088B (zh) * 2015-08-19 2018-05-22 深圳市阳光之路生物材料科技有限公司 一种可吸收手术缝合线及其制备方法
CN106474563B (zh) * 2016-12-02 2019-04-16 上海其胜生物制剂有限公司 一种反向温敏技术制备人工硬脑膜的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101480505A (zh) * 2009-01-23 2009-07-15 华南理工大学 一种表面功能化壳聚糖角膜修复材料的制备方法
CN102671240A (zh) * 2012-05-17 2012-09-19 浙江大学 一种多功能抗菌壳聚糖稳定凝胶涂层制备方法
WO2014152796A2 (fr) * 2013-03-14 2014-09-25 Hemcon Medical Technologies, Inc. Compositions biocompatibles et biorésorbables de chitosane dérivé
CN105079875A (zh) * 2015-08-19 2015-11-25 深圳市阳光之路生物材料科技有限公司 一种胸膜/脑膜及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101480505A (zh) * 2009-01-23 2009-07-15 华南理工大学 一种表面功能化壳聚糖角膜修复材料的制备方法
CN102671240A (zh) * 2012-05-17 2012-09-19 浙江大学 一种多功能抗菌壳聚糖稳定凝胶涂层制备方法
WO2014152796A2 (fr) * 2013-03-14 2014-09-25 Hemcon Medical Technologies, Inc. Compositions biocompatibles et biorésorbables de chitosane dérivé
CN105079875A (zh) * 2015-08-19 2015-11-25 深圳市阳光之路生物材料科技有限公司 一种胸膜/脑膜及其制备方法

Also Published As

Publication number Publication date
CN105079875A (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
Amirian et al. In-situ crosslinked hydrogel based on amidated pectin/oxidized chitosan as potential wound dressing for skin repairing
Dutta et al. Functional cellulose-based hydrogels as extracellular matrices for tissue engineering
EP3072536B1 (fr) Matériau d'endoprothèse composite biologique à filage électrostatique hydrophile, utilisé pour une régénération de tissus, et son procédé de préparation et son application
Yan et al. A novel and homogeneous scaffold material: preparation and evaluation of alginate/bacterial cellulose nanocrystals/collagen composite hydrogel for tissue engineering
CN1220528C (zh) 羧甲基壳聚糖/羧甲基纤维素防手术粘连膜及其制备方法
Wang et al. Improvement in physical and biological properties of chitosan/soy protein films by surface grafted heparin
CN102580166A (zh) 一种医用仿生透明薄膜植入材料及其制备方法和应用
CN110585474B (zh) 海洋生物多糖基复合海绵的制备方法、复合海绵及应用
CN104013995A (zh) 氧化壳聚糖接枝改性猪真皮胶原微纳纤维膜及其制备方法
WO2017028625A1 (fr) Timbre pleural/méningé et son procédé de préparation
CN110507842B (zh) 一种细菌纤维素/透明质酸/ε-聚赖氨酸功能型敷料及其制备方法
CN113663137B (zh) 复合生物补片及其制备方法及应用
Zhang et al. Self-assembly of chitosan and cellulose chains into a 3D porous polysaccharide alloy films: Co-dissolving, structure and biological properties
CN1155347C (zh) 一种可吸收性的人工硬脑膜及其制备方法
CN1775302A (zh) 壳聚糖－明胶海绵伤口敷料的制备方法
Yang et al. In situ exfoliated silk fibroin nanoribbons enhanced chitin hydrogel for bile duct restoration
CN110755173A (zh) 一种抗菌防渗漏硬脑膜修补片及制备方法
CN110180023B (zh) 一种高强度生物质组织工程支架材料的制备方法
CN108245700A (zh) 一种羟丙基甲基纤维素壳聚糖薄膜敷料及其制备方法
Yang et al. Facile mussel-inspired polymerization to facilitate biomimetic in situ homogeneous mineralization for bone regeneration
CN109646706A (zh) 利用静电纺丝法制备防瘢痕覆膜的方法及其产品和应用
CN103550833B (zh) 一种药物控释膜材料及制备方法
Han et al. Multifunctional hemostatic polysaccharide-based sponge enhanced by tunicate cellulose: A promising approach for photothermal antibacterial activity and accelerated wound healing
CN100484496C (zh) 含甲壳素的医用神经移植物的制备方法
WO2017028626A1 (fr) Suture chirurgicale absorbable et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16836489

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16836489

Country of ref document: EP

Kind code of ref document: A1